Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic
Authors:
- Seyed Alireza JavadiniaSJSeyed Alireza Javadinia
- Mona AriamaneshMAMona Ariamanesh
- Maryam NabavifardMNMaryam Nabavifard
- Pejman PorouhanPPPejman Porouhan
- Babak PeyroShabanyBPBabak PeyroShabany
- Danial Fazilat-PanahDFDanial Fazilat-Panah
- Farbod HatamiFHFarbod Hatami
- Ahmad GhasemiAGAhmad Ghasemi
- Gary H. LymanGLGary H. Lyman
- James S. WelshJWJames S. Welsh
- Mansoureh DehghaniMDMansoureh Dehghani
- 11 November 2021
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 40 (2) , 115-123
Abstract
Patients with cancer are at significantly greater risk of COVID-19 and its complications than the general population. Since IgG antibodies remain detectable well after infection with the SARS-CoV-2 virus, seroprevalence can be used to estimate the proportion of the cancer population previously infected and potentially immune to SARS-CoV-2. The current study is a multi-center, prospective observational study to assess the seroprevalence of SARS-CoV-2 IgG antibody in a cancer population referred for vaccination between April and June 2021. Of a total of 270 adult patients with cancer accrued, 16% reported a history of COVID-19 more than four weeks previously confirmed by PCR. At the same time, serologic positivity for SARSCoV2 IgG was found in 29% of patients prior to vaccination including nearly 20% of patients without a history of confirmed COVID-19. Seropositivity was significantly greater in females consistent with higher rates in patients with breast cancer and gynecologic cancers. A seroconversion rate of 79.5% was observed in cancer patients with a history of PCR confirmed COVID-19, less than observed in the general population. In multivariable analysis, gender and prior history of COVID-19 were both independently associated with seropositivity prior to vaccination. Follow-up is continuing of this cohort of patients with cancer following vaccination to assess antibody and clinical outcomes.Keywords
Funding Information
- Sabzevar University of Medical Sciences (400004)
- Shahid Beheshti University of Medical Sciences (29074)
This publication has 31 references indexed in Scilit:
- Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infectionClinical Microbiology and Infection, 2020
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyThe Lancet, 2020
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, IdahoJournal of Clinical Microbiology, 2020
- The COVID-19 Outbreak in Iran; The First Patient with a Definite DiagnosisInternational Journal of Infectious Diseases, 2020
- Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020JAMA, 2020
- Low prevalence of IgG antibodies to SARS‐CoV‐2 in cancer patients with COVID‐19International Journal of Cancer, 2020
- Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in ChinaNature Medicine, 2020
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyThe Lancet, 2020
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 OutbreakCancer Discovery, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020